Ritesh N Kumar
University of Michigan
6 Papers
53 Citations
Ritesh N Kumar is an academic researcher from University of Michigan. The author has contributed to research in topics: Patient satisfaction & Prescription costs. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease
Mark J. Atkinson,Anusha Sinha,Steven Hass,Shoshana S. Colman,Ritesh N Kumar,Meryl Brod,Clayton R Rowland +6 more
TL;DR: The Treatment Satisfaction Questionnaire for Medication (TSQM) as mentioned in this paper is a psychometrically sound and valid measure of the major dimensions of patients' satisfaction with medication.
Direct health care costs of 4 common skin ulcers in New Mexico Medicaid fee-for-service patients.
Ritesh N Kumar,Gireesh V. Gupchup,Melanie A. Dodd,Bijal M. Shah,Michael Iskedjian,Thomas R. Einarson,Dennis W. Raisch +6 more
TL;DR: The New Mexico Medicaid fee-for-service system incurred a total cost of approximately $11.6 million from 1994 through 1998 for the treatment of the 4 categories of skin ulcers studied, which showed that the majority of wounds were coded as pressure ulcers, which had the highest associated costs.
40
Hyperlipidemia in Native Americans: Evaluation of Lipid Management Through a Cardiovascular Risk Reduction Program
TL;DR: For more than 40 years, cardiovascular disease (CVD) has been the leading cause of death in the United States, however, in the general population, there has been a significant reduction in mortality associated with CVD since the mid-1960s.
10
The Relationship of Diabetes Mellitus Performance Indicators with Self-Reported Health and Patient Satisfaction
David P. Nau,Ritesh N Kumar +1 more
TL;DR: Patients who received more frequent HbA1c monitoring reported better health, and patients who received foot exams and diabetes education were more satisfied with the care they received for diabetes mellitus, when controlling for demographics, co-morbidities and severity of illness.
4
Quality assessment of economic analyses of pharmacological and nutritional therapy for hyperlipidemia
TL;DR: Treatment and policy implications are: secondary prevention is more cost-effective than primary prevention, the cost-effectiveness of lipid-lowering treatments correlates with risk-factors and statin drugs are more cost -effective than cholesterol-sequestering agents.
1